年間 6 号発行
ISSN 印刷: 1040-8401
ISSN オンライン: 2162-6472
Indexed in
Regulatory T-Cell Therapy in Transplantation and Severe Autoimmunity
要約
Current approaches to prevent or treat transplant rejection, graft-versus-host disease and severe autoimmunity rely on non-specific immunosuppressive drugs. Ongoing efforts aimed at harnessing regulatory T (Treg) cells hold promise for revolutionizing the current therapeutic options, reducing if not abandoning immune suppression in favor of immune tolerance. This paradigm shift carries the potential of dramatically enhancing efficacy, persistency, and specificity while reducing side effects. Here, we review the various strategies devised to manipulate Treg cells in vitro and in vivo, the clinical progress achieved to date, and critical issues that still need to be addressed.
-
Messina Samantha, Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis, Small GTPases, 11, 5, 2020. Crossref
-
Annoni Andrea, Gregori Silvia, Naldini Luigi, Cantore Alessio, Modulation of immune responses in lentiviral vector-mediated gene transfer, Cellular Immunology, 342, 2019. Crossref